Navigation Links
Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
Date:9/8/2008

ROCKVILLE, Md., Sept. 8 /PRNewswire-FirstCall/ -- Neuralstem Inc., CEO, Richard Garr, will be a featured panelist discussing stem cells and ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at the 2008 World Stem Cell Summit in Madison, Wisconsin, on September 22, at 2:00 CDT. In a presentation prior to the panel, Mr. Garr will talk about Neuralstem's plans for an ALS trial and give an update of the Company's filing status with the FDA.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )

The World Stem Cell Summit (http://www.worldstemcellsummit.com) is sponsored by the Genetics Policy Institute, the University of Wisconsin- Madison Stem Cell & Regenerative Medicine Center and WiCell Research Institute, Inc.

About Neuralstem

Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia.

Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury and ALS. The company's cells have extended the life of rats with ALS (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collaboration with Johns Hopkins University researchers, and also reversed paralysis in rats with Ischemic Spastic Paraplegia, as reported in NEUROSCIENCE on June 29, 2007, in collaboration with researchers at University of California San Diego. The Company expects to file its first IND (Investigational New Drug) application with the FDA for ALS in the fall.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward- looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10- KSB for the year ended December 31, 2007 and the quarterly report on form 10-Q for the period ended June 30, 2008.


'/>"/>
SOURCE Neuralstem Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neuralstem Shares Accepted for Trading on Amex(R)
2. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
3. Patent Office Rules in Neuralstems Favor in Dispute with StemCells, Inc.
4. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
5. Neuralstem Sues StemCells, Inc. Over New Patent
6. Neuralstem Responds to New StemCells, Inc. Lawsuit
7. Neuralstem Fills Key Product Development Position
8. Neuralstem Reports Second Quarter Financial Results and Highlights
9. AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium
10. Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit
11. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... ... April 20, 2017 , ... ... unique intellectual property (IP) sharing and commercialization model. , The Center for Advancing ... main component of this effort is bringing the IP to the attention of ...
(Date:4/20/2017)... and PETACH TIKVAH, Israel , April ... leading developer of adult stem cell technologies for neurodegenerative diseases, ... will present at the Alliance for Regenerative Medicine,s (ARM) 5 ... Thursday, April 27, 2017 at 09:40 EDT in ... Kern , MD, MHSc, Chief Medical Officer & Chief Operating ...
(Date:4/19/2017)... ... April 18, 2017 , ... The Vibrating Orifice Aerosol Generator ... generating monodisperse droplets of known diameters for research applications such as for calibrating ... by drying monodisperse droplets. , The VOAG requires forcing liquid out of ...
(Date:4/19/2017)... ... April 18, 2017 , ... Alisa Wright, founder and CEO of Singota ... College of Pharmacy in Lafayette, Indiana. , The Distinguished Alumni Award was established ... careers and other scientific endeavors. , Wright began her career in the pharmaceutical ...
Breaking Biology Technology:
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
Breaking Biology News(10 mins):